Vertex Pharmaceuticals (VRTX) Cost of Revenue (2009 - 2026)

Vertex Pharmaceuticals' Cost of Revenue history runs 18 years deep, the most recent figure standing at $392.8 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 8.21% year-over-year to $392.8 million; the TTM figure through Mar 2026 stood at $1.7 billion (up 8.4% YoY), while the FY2025 annual figure was $1.7 billion, up 7.89% from the prior year.
• Cost of Revenue for Q1 2026 stood at $392.8 million, down from $466.0 million in the prior quarter.
• The five-year high for Cost of Revenue was $466.0 million in Q4 2025, with the low at $245.8 million in Q1 2022.
• The 5-year median for Cost of Revenue is $363.0 million (2025), against an average of $348.1 million.
• The sharpest annual moves came in 2023 and 2025: Cost of Revenue grew 29.9% in 2023, then gained 5.65% in 2025.
• Vertex Pharmaceuticals' Cost of Revenue stood at $283.3 million in 2022, then advanced by 29.9% to $368.0 million in 2023, then climbed by 15.05% to $423.4 million in 2024, then rose by 10.06% to $466.0 million in 2025, then retreated by 15.71% to $392.8 million in 2026.
• Business Quant data shows VRTX's Cost of Revenue at $392.8 million in Q1 2026, $466.0 million in Q4 2025, and $414.8 million in Q3 2025.